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 Abstract 
 Background: Statins can cause tubular proteinuria by 
inhibiting tubular reabsorption of urinary proteins. To 
distinguish between microalbuminuria originating from 
glomerular leakage of albumin and tubular microalbu-
minuria due to statin therapy, the  α 1 -microglobulin/
albumin ratio is evaluated in patients taking statins and 
compared to untreated patients. 
 Methods: Ten apparently healthy subjects were 
given 40 mg of simvastatin and tested for urinary  α 1 -
microglobulin, albumin, creatinine and cystatin C, up to 
24 h after administration. Additionally, urine samples of 
76 statin-treated and 456 untreated patients presenting 
with micro-albuminuria (albuminuria range between 
20 and 200 mg/L) were tested for  α 1 -microglobulin and 
albumin.  α 1 -Microglobulin/albumin ratios were com-
pared. Total cholesterol was measured in 50 patients on 
statin therapy. 
 Results: In the 10 apparently healthy subjects, a signifi-
cant temporary increase of  α 1 -microglobulin, albumin 
and  α 1 -microglobulin/albumin ratio was observed after 
statin intake. In the group of 532 patients showing micro-
albuminuria, those treated with statins showed a signifi-
cantly higher mean urinary  α 1 -microglobulin/albumin 
ratio then untreated patients. Urinary albumin concentra-
tions were significantly higher in patients taking simva-
statin than in patients on rosuvastatin treatment and they 
were also higher in patients on statin therapy with a total 
serum cholesterol concentration below 3.88 mmol/L than 
in patients with a total serum cholesterol concentration 
above 5.17 mmol/L. 
 Conclusions : Tubular proteinuria, caused by the use of 
statins, can be distinguished from glomerular proteinuria 
by a higher urinary  α 1 -microglobulin/albumin ratio. 
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 Introduction 
 Statins lower cholesterol levels by inhibiting 3-hydroxy-
3-methylglutaryl CoA (HMG-CoA) reductase [ 1 ], which con-
verts HMG-CoA to mevalonate. Derivates of mevalonate, 
such as geranylgeranyl pyrophosphate (GGPP) play a 
major role in post-translational modification of a lot of 
proteins, especially GTP-binding proteins [ 2 ]. These pro-
teins are involved in the process of receptor-mediated 
endocytosis (RME), which occurs in the proximal tubular 
cells for albumin uptake [ 3 – 6 ]. This process involves 
megalin and cubilin receptors, which require the presence 
of prenylated GTP-binding proteins [ 7 ]. 
 By inhibiting HMG-CoA reductase and reducing pre-
nylation of GTP-binding proteins, statins inhibit protein 
uptake by the human proximal tubule. The reduced 
uptake of plasma proteins by the tubules may result in 
proteinuria in some patients treated with statins [ 2 ,  8 ]. 
Patients on statin therapy often suffer from conditions 
that can cause proteinuria, such as diabetes and arterial 
hypertension. In these patients, interpretation of microalbu-
minuria is hampered by the fact that microalbuminuria 
may either originate from glomerular leakage of albumin 
or from a statin-induced reduction of albumin uptake by 
the renal tubules. Proteinuria associated with statins may 
be a physiologic and benign response, related to altered 
protein reabsorption rather than an indication of dimi-
nished glomerular membrane integrity or frank toxicity. 
As microalbuminuria monitoring is recommended in the 
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follow-up of patients with diabetes and arterial hyper-
tension, correct interpretation is of practical importance 
[ 9 – 11 ]. 
 Correcting albuminuria for a disturbed tubular reab-
sorption can theoretically be achieved by comparing 
albuminuria to the concentration of a tubular marker 
protein which is taken up by the same receptor protein. 
Urinary  α 1 -microglobulin is a very stable protein and is 
considered as a robust marker for tubular reabsorption 
of proteins [ 12 ]. 
 In the present study, we evaluated the  α 1 -
microglobulin/albumin ratio to differentiate between 
proteinuria caused by risk factors and proteinuria caused 
by use of statins. Albumin and  α 1 -microglobulin are both 
ligands of the cubilin/megalin receptors and increased 
urinary concentrations of these proteins will be found in 
statin-induced tubular proteinuria [ 12 ,  13 ]. 
 Materials and methods 
 A group of 10 apparently healthy subjects (6 males, 4 females; 31 ± 13 
years) who were not treated with statins, angiotensin converting 
enzyme inhibitors or angiotensin receptor blockers were adminis-
tered 40 mg of simvastatin. Due to ethical concerns, we have only 
administered very modest amounts of weak statins (simvastatin is 
only a weak statin) in a single dose regimen: 40 mg of simvastatin 
(Zocor  ®  ) corresponds to only 5 mg of rosuvastatine (Crestor  ®  ). Urine 
specimens were collected prior to the intake of the drug, then hourly 
until six samples were obtained and fi nally 24 h aft er statin intake. 
 α 1 -microglobulin, albumin, cystatin C and creatinine were measured 
in urine. 
 Urinary albumin and serum cystatin C levels were measured 
by nephelometry (BN II). Urinary  α 1 -microglobulin was measured 
by turbidimetry and total serum cholesterol was measured with a 
standard colorimetric assay using Roche reagents on a Cobas 8000 
analyzer. Urinary creatinine was measured using a compensated 
Jaff e method on a Cobas 6000 analyzer (Roche). Urinary protein was 
assayed acco rding to Orsonneau et al. [ 14 ]. Concentrations of urinary 
proteins were expressed as mg protein/g creatinine. 
 Between January 2011 and October 2011, urine samples from 532 
patients (364 females, 168 males; 45 ± 19 years) showing micro-albu-
minuria were obtained. Seventy-six of them were taking statins: sim-
vastatin (n = 43), atorvastatin (n = 18), rosuvastatin (n = 12) and pravas-
tatin (n = 3). Specimens were tested for urinary albumin, urinary 
 α 1 -microglobulin and total urinary protein. In contrast to the group 
of healthy subjects (n = 10), urinary creatinine was not measured in 
the patient group. Concomitantly, in 50 patients taking statins, total 
cholesterol was measured in serum. 
 The study was approved by the Ethics Committee review board 
of the University Hospital of Ghent (EC 2012 – 374). The study com-
plied with the World Medical Association Declaration of Helsinki 
regarding ethical conduct of research involving human subjects. A 
written informed consent was obtained from all participants. Statis-
tical analysis was performed with the statistical program Medcalc 
(Medcalc, Mariakerke, Belgium). p-Values lower than 0.05 were 
considered statistically signifi cant. Data are reported as mean ± SD 
or median with interquartile range (IQR). Wilcoxon test for paired 
samples, Mann-Whitney U-test and Kruskal-Wallis tests were used 
as appropriate. 
 Results 
 In the group of apparently healthy subjects who had been 
administered a single dose of 40 mg of simvastatin, a 
transient increase of both  α 1 -microglobulin and albumin 
was observed ( Figure 1 ). At baseline, all 10 subjects had 
urinary albumin levels below 20 mg/L and urinary  α 1 -
microglobulin concentrations below 8 mg/L. Maximal 
concentrations were reached after 3 ± 1 h (albumin/
creatinine) and after 4 ± 2 h ( α 1 -microglobulin/creatinine 
and  α 1 -microglobulin/albumin). Maximal values for 
urinary  α 1 -microglobulin and albumin were respectively 
16.7 ± 9.8 mg/g creatinine and 14.5 ± 5.0 mg/g creatinine. 
The increase of  α 1 -microglobulin/creatinine, albumin/
creatinine and  α 1 -microglobulin/albumin ratio was sig-
nificant (p = 0.004, p = 0.048 and p = 0.002). Twenty-four 
hours after the administration of 40 mg of simvastatin, the 
levels of  α 1 -microglobulin and albumin returned to levels 
not significantly different from those prior to administra-
tion. All urinary cystatin C levels were below 1.04 mg/L at 
baseline, during the 6 h after administration and also 24 h 
after administration of simvastatin. 
 From the group of patients who were treated with 
statins (76 patients), 28 patients showed microalbu-
minuria (albuminuria between 20 and 200 mg/L) and 
10 patients had albuminuria  > 200 mg/L. The median 
albuminuria was 20.2 mg/L (IQR = 9.9 – 105.0 mg/L) in 
the statin group vs. 35.3 mg/L (IQR = 9.1 – 103.0 mg/L) in 
the non-statin group (p = 0.59). Median urinary concen-
tration of  α 1 -microglobulin was 9.3 mg/L (IQR = 3.6 – 21.9 
mg/L) in the statin group vs. 4.0 mg/L (IQR = 1.3 – 9.7 
mg/L) in the non-statin group (p < 0.0001). Median ratio 
of urinary  α 1 -microglobulin/albumin in the statin group 
was 0.4 (IQR = 0.1 – 0.8) vs. 0.1 (IQR = 0.0 – 0.4) in the non-
statin group. The ratios differed significantly between the 
treated and the untreated group (p < 0.0001) ( Table 1 ). 
 Linear regression for the urinary albumin and  α 1 -
microglobulin concentrations was performed for the 
statin group and the non-statin group. The regression 
equation for the non-statin group was y (urinary albumin, 
mg/L) = 74.3 (mg/L) + 0.6 × (urinary  α 1 -microglobulin, mg/L), 
for the statin group y (urinary albumin, mg/L) = 76.5 
(mg/L) + 1.2 × (urinary  α 1 -microglobulin, mg/L). As the 
slopes differed between the two groups, a mathematical 
correction could be proposed in order to compensate for 
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the effect of tubular reabsorption of albumin. As every 
mg increase of urinary  α 1 -microglobulin corresponded 
to a microalbuminuria of 74.3 mg + 0.6 × (urinary  α 1 -
microglobulin) in the non-statin group vs. a microalbumi-
nuria value of 76.5 mg + 1.2 × (urinary  α 1 -microglobulin) in 
the statin group, the following mathematical correction 
could be made in patients on statin therapy: microalbu-
minuria (corrected, mg/L) = microalbuminuria (measured, 
mg/L) – 0.6 × (urinary  α 1 -microglobulin, mg/L). 
 Urinary  α 1 -microglobulin, albumin and  α 1 -
microglobulin/albumin ratios were compared between 
the different types of statins:  α 1 -microglobulin levels 
did not differ significantly between the patients taking 
atorvastatin, pravastatin, rosuvastatin and simvastatin 
(p = 0.9). Albuminuria was significantly different among 
the various types of statins prescribed (p = 0.04): urinary 
albumin was significantly higher in patients taking simva-
statin (n = 43) than in patients taking rosuvastatin (n = 12) 
( Table 2 ). No significant difference was found for the 
urinary  α 1 -microglobulin/albumin ratio between the dif-
ferent type of statins (p = 0.3). 
 From 50 patients who were on statin therapy, the 
concentration of total serum cholesterol was measured. 
Patients were divided in three groups: patients with total 
serum cholesterol below 3.88 mmol/L, total serum cho-
lesterol between 3.88 mmol/L and 5.17 mmol/L and total 
serum cholesterol exceeding 5.17 mmol/L. The urinary 
albumin concentration was significantly higher in patients 
with serum cholesterol values below 3.88 mmol/L than in 
patients with a serum cholesterol concentration exceed-
ing 5.17 mmol/L (p = 0.02). Urinary albumin levels were not 
significantly different between the patients with a serum 
cholesterol level between 3.88 and 5.17 mmol/L and the 
two other groups. No significant difference was found 
for urinary  α 1 -microglobulin levels and  α 1 -microglobulin/
albumin ratio between the three groups. 
 Median total serum cholesterol concentrations of six 
patients taking rosuvastatin (1 × 10 mg/day, 3 × 20 mg/day 
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 Figure 1   Urinary albumin concentration according to serum cholesterol level. 
 The patient group (n = 50) was divided in three groups: group 1 (n = 20) with a total serum cholesterol concentration   ≤  3.88 mmol/L, group 
2 (n = 13) with a total serum cholesterol concentration ranging from 3.88 to 5.17 mmol/L and group 3 (n = 17) with a total serum cholesterol 
concentration   ≥  5.17 mmol/L. In the high cholesterolemia group (serum cholesterol exceeding 5.17 mmol/L), albuminuria is significantly 
(p = 0.02) lower than in the low cholesterolemia group (cholesterolemia below 3.88 mmol/L). 
 Table 1   Comparison of  α 1 -microglobulin, albumin and the  α 1 -microglobulin/albumin ratio in urine for the statin vs. the non-statin group. 
  Statin group (n = 76)  Non-statin group (n = 456)  p-Value 
 α 1 -Microglobulin, mg/L  9.3 (3.6 – 21.9)  4.0 (1.3 – 9.7)  < 0.0001 
 Albumin, mg/L  20.2 (9.9 – 105.0)  35.3 (9.1 – 103.0)  0.59 
 Ratio  α 1 -microglobulin/albumin  0.4 (0.1 – 0.8)  0.1 (0 – 0.4)  < 0.0001 
 α 1 -Microglobulin concentrations and the  α 1 -microglobulin/albumin ratio were significantly higher in the statin vs. the non-statin group 
(p < 0.0001). Data were reported as median and interquartile range. 
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and 2 × 40 mg/day) and 26 patients on simvastatin therapy 
(19 × 20 mg/day and 7 × 40 mg/day) were compared because 
the urinary albumin concentration was significantly diffe-
rent in both groups. Median total serum cholesterol level 
was 5.56 mmol/L (IQR = 4.76 – 5.66 mmol/L) in the patients 
on rosuvastatin therapy vs. 4.14 mmol/L (IQR = 2.59 – 6.23 
mmol/L) in patients on simvastatin therapy. 
 Discussion 
 The aim of the study was to distinguish microalbumin-
uria originating from glomerular leakage of albumin and 
tubular microalbuminuria due to statin therapy. All 10 
healthy subjects who were administered a single dose of 40 
mg simvastatin, showed a significant increase in urinary 
 α 1 -microglobulin, albumin and  α 1 -microglobulin/albumin 
ratio. This increase was transient as 24 h after administra-
tion, all urinary protein levels decreased to levels as before 
administration. Urinary cystatin C levels at baseline were 
all below 1.04 mg/L. After administration, up to 24 h after 
administration, levels never exceeded this value. 
 In patients, treated with statins, microalbuminuria 
can be observed in a large number of patients. These data 
are in agreement with earlier findings [ 2 ,  8 ,  15 ]. In a study 
of van der Tol et al. [ 16 ], statins were independently asso-
ciated with an increased prevalence of microalbuminuria, 
even after correction for  ‘ bias by indication ’ . The research-
ers created a propensity score for statin use to correct for 
this  ‘ bias by indication ’ . Propensity score analysis is a 
well-established method to adjust for confounding factors 
by indication in observational trials [ 17 ,  18 ]. The propensity 
model included the following variables that were deemed 
to be possibly related to statin use: age, gender, body mass 
index (BMI), waist circumference, systolic blood pressure, 
previous cardiovascular event, C-reactive protein (CRP), 
fasting glucose, diabetes, serum uric acid, high-density 
lipoprotein (HDL) and low-density lipoprotein (LDL) 
cholesterol, triglycerides, use of angiotensin converting 
enzyme inhibitor/angiotensin receptor blocker (ACE-I/
ARB) and smoking. Except for uric acid, the authors did 
not take renal function parameters into account, such as 
cystatin C. 
 α 1 -Microglobulin is a marker of tubular proteinuria 
which occurs in patients with a normal glomerular filtra-
tion rate, but with a diminished capacity of the proximal 
tubules to reabsorb and catabolize proteins [ 12 ]. The quan-
titative measurement in urine of total protein, albumin,  α 1 -
microglobulin, IgG and  α 2 -macroglobulin is useful to diffe-
rentiate the origin of proteinuria and hematuria [ 19 – 23 ]. 
Apart from  α 1 -microglobulin, many other urinary proteins 
are catabolized by the same megalin/cubilin pathway: 
vitamin D-binding protein [ 24 ,  25 ],  β 2 -microglobulin [ 26 ], 
transferrin [ 27 ] and retinol-binding protein [ 28 ], which are 
all markers of tubular proteinuria. The excretion of urinary 
 α 1 -microglobulin was significantly higher in statin-treated 
patients compared to statin untreated patients. Kostapa-
nos et  al. showed that rosuvastatin induced a small but 
significant increase in the excretion of  α 1 -microglobulin 
(by 16%, p < 0.05), indicating that statin-related proteinu-
ria involves low-molecular-weight proteins and is of proxi-
mal tubular origin [ 29 ]. The present study demonstrated 
that the urinary  α 1 -microglobulin/albumin ratio differs 
significantly between statin-treated and untreated indi-
viduals. One explanation may be that albumin and  α 1 -
microglobulin are taken up by the same megalin/cubilin 
receptor, localized in the renal tubules, which requires 
the presence of small GTP-binding proteins. However, 
as mentioned earlier, statins inhibit the biosynthesis of 
several intermediates of the mevalonate pathway. Statin-
induced microalbuminuria should also be differentiated 
from a possible renal bleeding, which is characterized by 
an  α 1 -microglobulin/albumin ratio  < 0.7 in combination 
with a positive urine dip test result (test strip for hemo-
globin positive  +  +  + ). The additional measurement of the 
 Table 2   Urinary  α 1 -microglobulin, albumin,  α 1 -microglobulin/albumin ratio and total serum cholesterol levels in the different types of 
statins. 
  Simvastatin (n = 43)  Atorvastatin (n = 18)  Rosuvastatin (n = 12)  p-Value 
 Urinary albumin, mg/L  26.7 (11.5 – 135.7)  26.0 (9.1 – 135.0)  14.4 (9.1 – 20.7)  0.04 
 Urinary  α 1 -microglobulin, mg/L  11.2 (4.2 – 21.5)  7.6 (4.9 – 20.6)  4.7 (2.0 – 30.5)  0.9 
 α 1 -Microglobulin/albumin ratio 
(urine) 
 0.4 (0 – 0.8)  0.2 (0.1 – 0.5)  0.5 (0.2 – 1.5)  0.3 
 Total serum cholesterol, 
mmol/L 
 4.14 (2.59 – 6.23)  4.16 (3.44 – 4.32)  5.56 (4.76 – 5.66)  0.07 
 Urinary albumin was significantly higher in patients taking simvastatin than in patients taking rosuvastatin (p = 0.04). Data were reported as 
median with interquartile range. Pravastatin was not included in the data because the group is too small (n = 3). 
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IgG/albumin and  α 2 -macroglobulin/albumin ratios might 
be helpful in this condition [ 22 ,  23 ]. However as the clini-
cal presentation of a patient with a renal hemorrhage is 
totally different from the presentation of a patient with 
microalbuminuria from tubular overflow (statin)-induced 
microalbuminuria, it should be easy for clinicians to diffe-
rentiate both conditions. 
 Although the urinary albuminuria values induced by 
statins are only slightly above the reference range, our 
mathematical formula is important as it makes it possible 
to distinguish this mild proteinuria from microalbumin-
uria caused by glomerular damage. The reported changes 
in urinary  α 1 -microglobulin concentration (and in urinary 
 α 1 -microglobulin/albumin ratio) are statistically signifi-
cant as the values increase by a factor of 2.32. For a sen-
sitive assay with a CV of a few percent, this significant 
temporary increase illustrates an impaired protein reab-
sorption capacity by the tubules. In the present study, 
starting  α 1 -microglobulin levels of the volunteers taking 
statins were within the reference values (as expected for 
a good control group). However, a 232% increase remains 
impressive in people with a normal tubular function. Due 
to ethical concerns, only very modest amounts of weak 
statins (simvastatin is only a weak statin) were adminis-
tered in a single dose regimen. 
 There was a difference between the urinary albumin 
levels in patients taking either rosuvastatin or simva-
statin. Patients on simvastatin therapy had significantly 
more urinary albumin than patients on rosuvastatin 
therapy. When we investigated the cholesterol levels in 
serum in 50 patients on statin therapy, lower serum chole-
sterol levels (below 3.88 mmol/L) were significantly asso-
ciated with higher urinary albumin concentrations than 
in patients with serum cholesterol values exceeding 5.17 
mmol/L. This could be explained by a more profound 
effect of statins in these patients and as a consequence 
a higher prevalence of microalbuminuria. So the urinary 
albumin levels are not dependent on the drug but on the 
cholesterol levels. 
 The data clearly highlight the difficulties in inter-
preting microalbuminuria values in patients treated with 
statins, since two distinct mechanisms might be involved: 
glomerular damage and an impaired tubular reabsorp-
tion. As the statin-induced microalbuminuria is mostly of 
tubular origin, it is uncertain and rather unlikely whether 
it has the same prognostic impact for renal and cardio-
vascular disease as endothelial dysfunction-induced 
glomerular microalbuminuria [ 16 ]. The suggested correc-
tion factor is based on the difference between the slopes 
of urinary albumin and  α 1 -microglobulin concentrations 
between the treated and untreated patients. When micro-
albuminuria is measured in a patient on statin therapy, this 
value could be corrected with the following mathematical 
correction: microalbuminuria (corrected) (mg/L) = micro-
albuminuria (measured) (mg/L) – 0.6 × (urinary  α 1 -
microglobulin, mg/L). This formula is particularly useful 
for patients with microalbuminuria to estimate the effect 
of statin use on the proteinuria level. Also in conditions of 
mixed (glomerular and tubular) proteinuria, our findings 
should be taken into account. However in case of macroalbu-
minuria, the clinician should look for an underlying renal 
pathology. It was not the aim of our study to differentiate 
statin-induced proteinuria from other conditions associ-
ated with tubular proteinuria. However, we definitely 
propose to include the urinary  α 1 -microglobulin/albumin 
ratio in a standard laboratory form, as this ratio could 
be helpful in distinguishing glomerular proteinuria from 
tubular overflow (statin)-induced albuminuria. 
 In conclusion, albuminuria caused by increased 
glomerular leakage can better be distinguished from the 
effect of concomitant tubular proteinuria by using a math-
ematical correction when microalbuminuria is measured 
in a patient on statin therapy. 
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